Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05329935 · ClinicalTrials.gov registry record
Congenital Athymia Patient Registry
A clinical trial of Complete DiGeorge Anomaly and Complete DiGeorge Syndrome, sponsored by Sumitomo Pharma Switzerland.
- Recruiting
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT05329935: Recruiting study of Complete DiGeorge Anomaly and Complete DiGeorge Syndrome, sponsored by Sumitomo Pharma Switzerland.
NCT05329935 is a study of Complete DiGeorge Anomaly and Complete DiGeorge Syndrome that is actively recruiting participants, run by Sumitomo Pharma Switzerland. The registered enrollment target is 75 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05329935, a study of Complete DiGeorge Anomaly and Complete DiGeorge Syndrome, is actively recruiting participants, sponsored by Sumitomo Pharma Switzerland.
- RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC. Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (AESI).
Conditions Studied
Interventions
- BIOLOGICAL Cultured Thymus Tissue
Study Locations (1)
North Carolina
- Duke University School of Medicine - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2026-04 |
What NCT05329935 shows while recruiting
NCT05329935 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target.
The record links to 3 conditions, with Complete DiGeorge Anomaly appearing as the primary indexed condition, and to 1 intervention - of which Cultured Thymus Tissue is the first listed.
NCT05329935 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05329935 about?
NCT05329935 is a clinical study titled "Congenital Athymia Patient Registry". This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC. Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution ...
What is the current status of trial NCT05329935?
This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2022-05-25. Estimated completion is 2026-04.
What conditions does trial NCT05329935 study?
This clinical trial studies the following conditions: Complete DiGeorge Anomaly, Complete DiGeorge Syndrome, Congenital Athymia.
What interventions are being tested in trial NCT05329935?
The interventions under investigation include: Cultured Thymus Tissue (BIOLOGICAL).
Who is sponsoring clinical trial NCT05329935?
This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05329935 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Complete DiGeorge Anomaly
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI